U.S. Markets open in 2 hrs 30 mins

Nuvilex Is Beneficiary of Doctors' Approach Toward Medical Marijuana

BALTIMORE, MD--(Marketwired - Jun 12, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes based on a recent poll, Nuvilex ( OTCQB : NVLX ) is beneficiary of many doctors' approach toward medical marijuana. The Company is an international firm engaged in using its live-cell encapsulation technology as part of treatments for pancreatic and other cancers along with the development of therapies based on components of medical marijuana for the treatment of oncology patients.

A key driver in the success of clinical marijuana treatment initiatives and programs is strong support and a real desire for the introduction of new therapies by the medical community itself. A recent poll published in the May 30, 2013 edition of The New England Journal of Medicine shows that 76% of poll participants are in favor of the use of marijuana for medicinal purposes. Interestingly, only 1% of the voters in Utah supported the notion while 96% of the voters in Pennsylvania were in favor.

This amazing figure bodes extremely well for companies like Nuvilex. Interestingly, while much of the attention regarding medical marijuana development and research has centered on pain management, appetite, and mood, etc., this poll, much like Nuvilex's focus was focused on cancer treatment. In the poll, doctors surveyed were given a hypothetical case about a woman named "Marilyn" a 68-year-old woman with breast cancer that had metastasized and were asked if they would give her medical marijuana to help her with her symptoms.

As noted above over three-fourths of those surveyed in the poll answered in the affirmative. Therefore, it can be assumed that as Nuvilex enters into comprehensive studies into the effect of cannabidiol (CBD) as a possible treatment for cancer, the Company should have no shortage of supporters from potential subjects and more importantly, from the medical community. Many prospective patients and their doctors clearly wish to see these alternative forms of treatment studied further and broadly used as a real therapy.

A copy of this article as well as other articles and Nuvilex reports and disclaimers can be accessed by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. ( OTCQB : NVLX ): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.